Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: Comparison to prostatic biopsy;Rendimiento diagnóstico de la detección de células prostáticas malignas en la circulación sanguínea para la detección precoz de cáncer prostático: UNA comparación con la biopsia prostática

Archivos Espanoles de Urologia

Volumn 64, Issue 10, 2011, Pages 961-971

  Murray, Nigel P ^a,b,c   Reyes, E ^a   Tapia, P ^a   Orellana, N ^a   Duenas R ^a   Fuentealba, C ^a   Badinez, L ^d  

^a Department of Oral and Maxillofacial Surgery   (Chile)

^b Instituto de Bio Oncología   (Chile)

^c UNIVERSIDAD MAYOR   (Chile)

^d Centro Oncológico Fundación Arturo López Pérez   (Chile)

Author keywords

Circulating tumor cells; Digital rectal examination; Micrometastasis; Prostate biopsy; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; COMPARATIVE STUDY; EARLY DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; STATISTICAL MODEL; TUMOR EMBOLISM;

AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84555219885     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Pungalia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Impact of age, benign prostatic hyperplasia and cancer on prostate specific antigen level. Cancer 2006; 106: 1507-13.
2. Bozeman CB, Carver BS, Eastham JA, Veneble DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002; 167: 1723-6. (Pubitemid 34240711)
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. Cancer J Clin 2006; 56: 106-30.
4. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate specific antigen test. Urology 2006; 67: 762-8.
5. Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P et al. Discrimination of benign from malignant prostate disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002; 168: 1917-22.
6. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C et al. A multicenter clinical trial of the use of (-5, -7) pro prostate specific antigen. J Urol 2005; 174: 2150-3. (Pubitemid 41611761)
7. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Leoning SA. Molecular forms of prostate specific antigen and human kallikrien 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 1133-47.
8. Villaneuva J, Schaffer DR, Phillip J, Chaporro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor specific serum peptidone patterns. J Clin Invest 2006; 116: 271-84. (Pubitemid 43121812)
9. Moreno JG, Croce CM, Fischer R, Monne M Vihka P, Mulholland SG et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52: 6110-6112
10. Zhou M, Chinnaiyan AM, Lleer CG et al. Alpha-methylacyl- CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26: 926-31. (Pubitemid 34747646)
11. Beach R, Gown AM, Peralta-Venturina MN et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol 2002; 26: 1588-96. (Pubitemid 35387221)
12. Campbell I, Meredith F. (Meredith Fairfax). II. Wein, Alan J. III. Kavoussi, Louis R. IV. Campbell's urology. V. Section II, chapter 3.
13. Ouzzane A, Coloby P, Mignard JP, Allegre JP, Soulie M, Rebillard X, Salomon L, Villers A; Recommendations for best practice for prostate biopsy Prog Urol. 2011 Jan;21(1):18-28.
14. Borgen E, Naume B, Nesland JM, Kvalhein E, Beiske K, Fodsted O et al. Standardization of the immunocitochemical detection of cancer cells in bone marrow and blood: Establishment of objective criteria for the evaluation of immunostained cells. ISHAGE Cytotherapy 1999; 5: 377-88
15. Rubin MA, Zhou M, Dhanasekaran SM. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-70. (Pubitemid 34289218)
16. TMN classification
17. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V et al. Screening and prostate cancer mortality in a randomized European Study. NEJM 2009; 360: 1320-8.
18. Andiole GL, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN et al. Mortality results from a randomized prostate cancer screening trial. NEJM 2009; 360: 1310-19.
19. Mistry K, Cable G. Meta-analysis of PSA and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16: 95-101
20. Murray NP, Calaf GM, Badinez L, Dueñas R, Badinez O, Orellana N, et al. P504S expressing circulating prostate cells as a marker for prostate cancer. Oncology Reports 2010; 24: 687-692.
21. Lodding P, Aus G, Bergdahl S. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3-4ng/ml PSA. J Urol 1998; 159: 899-903 (Pubitemid 28106553)
22. NCCN Clinical Oncology Guidelines 2010. www.nccn.org
23. McGee S. Simplifying likelihood ratios. J Gen Intern Med 2002; 17: 646-649
24. Murray NP, Reyes E, Badínez L, Orellana N, Dueñas R, Fuentealba C. Detección y características de células prostáticas circulantes primarias, asociación con la presencia de micrometástasis y las implicaciones para el tratamiento quirúrgico en hombres con cáncer prostático. Arch. Esp. Urol. 2010; 63: 345-53
25. Eschwège P, Moutereau S, Droupy S, Douard R, Gala JL, Benoit G, Conti M, Manivet P, Loric S. Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer. 2009 Feb 24;100(4):608-10.
26. Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008 Jun;179(6):2187-91; discussion 2191.
27. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L et al. Isolation and characterization of circulating tumor cell from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 25: 25
28. Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B et al High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007; 18: 518-21 (Pubitemid 46359632)
29. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochemistry and Cell biology 2008; 129 705-733
30. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez- Espinoza R, Anand A et al. Circulating prostate tumor cells detected by RT-PCR in men with localized or castrate refractory prostate cancer: concordance with CellSearch assay and association with bone metastasis and with survival. Clin Chem 2009; 55: 765-773
31. Schaffer DR, Leversha MA, Danila DC. Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer. Clin Cancer Res 2007; 13: 2023-2029 (Pubitemid 46649868)
32. Went PT, Lugli A, Meier S et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 1: 122-128 (Pubitemid 38133932)
33. Paterlini-Brechot P, Benali NL. Circulating tumor cells detection: clinical impact and future directions. Cancer Letters 2007; 2: 180-204 (Pubitemid 47017533)
34. Raimondi C, Gradilone A. Naso G, Vincenzi B, Petracca A, Nicolazzo C et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011; Feb 5 (Epub ahead of print).
35. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T et al. Detection of EpCAM negative and cytokeratin negative circulating tumor cells in peripheral blood. J Oncol 2011; (epub 2011 252361 Apr 19)
36. Panteleakou Z, Lembessis P. Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, Koutsilieris m. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls andclinical relevance. Mol Med 2009; 15: 101-14
37. Fehm T, Sotomayer EF, Meng S, Tucker T, Lane N, Wang J, Gebauer G. Methods for isolating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7:171-85 (Pubitemid 40872753)
38. Resel L, Olivier C, San José L, Veganzones S, Galante I, Vidaurreta M et al., Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation. Arch Esp Urol. 2010 ;63:23-31.
39. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21: 729-33
40. Rietbergen JB, Kruger AE, Kranse R, Schroder F. Complications of transrectal ultrasound guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population based screening program. Urology 1997; 49: 875-80. (Pubitemid 27246956)
41. Vallejos T, Gonzalez G. Complicaciones en biopsia prostática transrectal ecoguiada Rev Chil Urol 2003; 68: 143-145.